U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Wed Apr 02 20:00:01 GMT 2025
Edited
by admin
on Wed Apr 02 20:00:01 GMT 2025
Protein Type BISPECIFIC ANTIBODY
Protein Sub Type IGG1|KAPPA
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
VT894H6T3S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Velinotamig
INN  
Official Name English
H-gamma1 heavy chain anti-CD3E Homo sapiens (1-445) [VH (Homo sapiens IGHV3-33*01 (94.9%) -(IGHD) -IGHJ2*01 (88.2%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*03 G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v39 CH2 F1.3, E1.2, S116, G1
Preferred Name English
Immunoglobulin G1 [141-glutamic acid,207-aspartic acid,218-threonine,235-phenylalanine,236-glutamic acid,269-glutamine,275-glutamine,332-serine,350-cysteine,356-glutamine,367-serine,369-alanine,408-valine,420-glutamic acid], bispecific, anti-(human tumor
Common Name English
immunoglobulin H-gamma1_L-kappa/H-gamma1_L-kappa, anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)] and anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)], Homo sapiens
Common Name English
velinotamig [INN]
Common Name English
Code System Code Type Description
NCI_THESAURUS
C211815
Created by admin on Wed Apr 02 20:00:01 GMT 2025 , Edited by admin on Wed Apr 02 20:00:01 GMT 2025
PRIMARY
CAS
2848586-49-0
Created by admin on Wed Apr 02 20:00:01 GMT 2025 , Edited by admin on Wed Apr 02 20:00:01 GMT 2025
PRIMARY
INN
13145
Created by admin on Wed Apr 02 20:00:01 GMT 2025 , Edited by admin on Wed Apr 02 20:00:01 GMT 2025
PRIMARY
SMS_ID
300000056809
Created by admin on Wed Apr 02 20:00:01 GMT 2025 , Edited by admin on Wed Apr 02 20:00:01 GMT 2025
PRIMARY
FDA UNII
VT894H6T3S
Created by admin on Wed Apr 02 20:00:01 GMT 2025 , Edited by admin on Wed Apr 02 20:00:01 GMT 2025
PRIMARY
From To
4_134 4_194
4_23 4_88
3_134 3_194
3_23 3_88
2_365 2_423
2_259 2_319
2_221 4_214
2_145 2_201
2_22 2_96
1_368 1_426
1_262 1_322
1_230 2_227
1_227 2_224
1_224 3_214
1_148 1_204
1_22 1_96
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_298
N 2_295
Related Record Type Details
CD3
CD3
TARGET -> ACTIVATOR
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17
TARGET->LIGAND
Related Record Type Details
Velinotamig
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID REMOVAL [1_448] [2_445] C-TERMINUS K LYSINE K3Z4F929H6
AMINO_ACID_SUBSTITUTION [1_1] [2_1] N-TERMINUS Q PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966